Ultrasonic Detection Liver Fibrosis

Abstract

A large amount of information accumulated as a result of purely laboratory studies of liver fibrosis (AF) over the past 20 years now allows practical hepatologists to develop therapeutic measures for the profiling and treatment of this pathology. This information reflects not only understanding molecular basis for the development of AF, but also makes it possible to improve methods for diagnosing liver diseases. The progress made has led to the clear understanding that cirrhosis of the liver is reversible, and to realistic expectations that effective antifibrotic therapy will significantly change the management of patients with liver disease and provide favorable prognosis even with developed liver cirrhosis .

As a result, clinicians can view AF in a new light—as a clinical problem amenable to specific diagnostic tests and treatments that are independent. from etiology. This review is an attempt to highlight the most recent advances in the study of the molecular and biological basis of the development of AF and its prognosis in various liver diseases with already known development mechanisms.

Liver cirrhosis (LC) can be defined as the last stage of AF, as a result of which in the liver parenchyma nodular structures are formed and thus the function is disrupted liver. This definition implies that CPU is an irreversible phenomenon, but At present, there is sufficient evidence of the reversibility of this process.

Fibrosis and cirrhosis of the liver are a consequence of the constant effect on the liver parenchyma of various types of damaging agents (viral, autoimmune, medicinal, cholestatic) and one of the outcomes of metabolic disorders in the liver itself. hepatocytes.